BioSpace News Archive

Viracta Therapeutics, Inc. (Nasdaq: VIRX) today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.

Alphatec Holdings, Inc., a provider of innovative solutions dedicated to revolutionizing the approach to spine surgery, announced the pricing of an underwritten registered offering of 4,285,715 shares of common stock at an offering price of $14.00 per share.

DBV Technologies announced that DBV has received written responses from the U.S. Food and Drug Administration on the regulatory path for investigational Viaskin™ Peanut 250 μg patch in toddlers ages 1 – 3 years-old with a confirmed peanut allergy.

A drug called teriflunomide may delay first symptoms for people whose magnetic resonance imaging (MRI) scans show signs of multiple sclerosis (MS) even though they do not yet have symptoms of the disease.

Psygen Industries Ltd. (together with its subsidiaries, “Psygen”) is pleased to announce that its wholly-owned subsidiary, Psygen Labs Inc., completed manufacture of more than 1.5 million microdoses of lysergic acid diethylamide (“LSD”). A portion of the LSD has been exported to New Zealand for use in a ground-breaking Phase II clinical trial sponsored by MindBio Therapeutics

Innovent Biologics, Inc., announced that the overall survival results of the Phase 2 study of pemigatinib in Chinese patients with advanced cholangiocarcinoma were presented at the American Association for Cancer Research Annual Meeting 2023.

Modalis Therapeutics Corporation announced that the abstract has been accepted for a presentation in the late-breaking session at the 26th Annual Meeting of The American Society of Gene & Cell Therapy, being held in Los Angeles CA on May 16-20, 2023.

ANGLE plc is delighted to announce it has signed an agreement with BioView Ltd. to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer utilising ANGLE’s FDA cleared Parsortix® PC1 Clinical System to harvest CTCs and BioView’s automated microscopy systems and software to detect and assess the HER2 expression and/or gene amplification in CTCs.

Biophytis SA announced that it has received written notification from the Nasdaq Stock Market LLC dated April 14, 2022, indicating that Biophytis has regained compliance with he Nasdaq Global Select Market minimum bid price requirement.

NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, announces the appointment of Vad Lazari Ph.D. who joins in the newly created position of VP of Biology, to be based in the Company’s facilities in Stevenage.